Collagen Crosslinked C-telopeptide
Osteoporosis is a major cause of morbidity and mortality among the aging population in the world. To aid in the identification and treatment of those diagnosed with the risk of osteoporotic fracture, a number of biochemical bone turnover markers (BTMs) have been developed.
Approximately 90% of bone and tissue consists of type 1 collagen. Collagen is a group of proteins that mesh together and strengthen the bone structure. Type 1 collagen is derived from type 1 procollagen, which has two propeptides (C-terminal and N-terminal) on each end of its molecule. Certain proteases will react with the propeptide and cleave the terminal ends from the molecule before they are assembled into collagen fibers. The rate of synthesis of type I collagen can be determined by measuring C-terminal (PICP) and N-terminal (PINP) propeptides. Therefore, monitoring these markers will monitor bone remodeling and turnover. Increased levels can indicate normal growth as well as bone disease. Bone disease is characterized by imbalance in bone turnover that occurs when there is a disorder in formation and resorption.
C-terminal telopeptide of type I collagen (CTX), also know as Beta C-terminal telopeptide, is a specific reabsorption marker for degradation of bone type collagen I by osteocalasts, bone cells active in bone remodeling. CTX is derived from C-terminal propeptide after conversion of an alpha-aspartic acid to beta form of aspartic acid as the bone ages. Thus, CTX is a specific marker for degradation of collagen I in bone. Serum CTX assays measure a fragment of the C-terminal telopeptide of type 1 collagen released during resorption of mature bone. Therefore, elevated levels of CTX are associated with increase bone resorption and turnover.
- Detects increased bone turnover - used to identify patients at risk of fracture
- Helps to monitor antiresorptive and anabolic therapy in patients with osteoporosis
- As an aid in diagnosis and management of osteoporosis
- Complements and correlates with bone mineral density measurement
- Assesses type 1 collagen turnover in Paget’s disease of the bone
- Assesses bone metastases in certain bone malignancies
Increased in:
- Normal growth
- Osteoporosis
- Osteopenia
- Celiac Disease
- Primary hyperthyroidism
- Rheumatoid Arthritis
- Growth Hormone deficiency (non-adult onset)
- Paget’s Disease
- Healing fractures
- Hyperparathyroidism
Decreased in:
- Acute bone turnover suppression in oral glucose therapy
- Renal failure
- Adynamic bone disease
- Therapeutic response (i.e. decrease relative to baseline)
- When using test to monitor osteoporosis therapy, recommend initial testing prior to beginning therapy and reevaluate 3-6 months after starting therapy
Men pg/ml
18 - 29 y 87-1200
30 - 39 70-780
40 - 49 60-700
50 - 68 87-345
Women pg/ml
18 - 29 64-640
30 - 39 60-650
40 -49 40-465
Most stable in EDTA plasma (Lavender). Serum (SST), plain red top can be used if blood is processed promptly within 2-4 hours after collection.
Stability
- Ambient: 2-3 days
- Refrigerated: 7 days
- Clinical Biochemistry. 2012; 45: 928-935.
- Clinica Chimica Acta. 2004; 350: 167-173
- Bone Miner Res. 1999; 14(9):1614-21. [PMID: 10469291]
- J Clin Pharmacol. 2002; 42(3):190-6. [PMID: 11865965]
- Bone. 1998; 23(5):471-7. [PMID: 9823455]
- Scand J Clin Lab Invest. 2002; 62(3):237-43. [PMID: 12088343]
- Endes DB and Rude RK. “Mineral and Bone Metabolism.” Tietz Textbook of Clinical Chemistry, 3rd ed. Burtis CA, Ashwood ER (eds). Philadelphia, PA: WB Saunders Co, 1999, 1349-457.